Composition containing probiotics for improving oral and intestinal flora, oral microeffervescent tablet and application of oral microeffervescent tablet
By combining Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus salivary, Lactobacillus Swiss, Bifidobacterium longum and apigenin in a specific proportion, the prepared probiotic composition significantly improved the symptoms of insomnia and solved the effect of a single probiotic Limited issues provide safe and effective ways to improve sleep.
Patent Information
- Application Number
- CN202410984964.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively relieve insomnia symptoms when using a single probiotic, and non-benzodiazepine sleeping pills have side effects, resulting in limited use.
Lactobacillus acidophilus NCFMTM, Bifidobacter lactis Bi-07TM, Lactobacillus salivary HA-118, Lactobacillus Swiss Lafti L10, Bifidobacter longus R0175, Lactobacillus rhamnosus R0011 and apigenin were combined in a specific proportion to Compositions to improve oral and intestinal flora are prepared for the preparation of oral microeffervescent tablets to improve sleep.
It significantly prolongs the duration of sleep in mice, has better effects than a single probiotic or apigenin combination, and has no toxic side effects, providing a safe and effective solution to improve sleep.
Smart Images

Figure BDA0004957124050000071 
Figure BDA0004957124050000081
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and in particular to a composition containing probiotics for improving oral and intestinal flora, an oral micro-effervescent tablet and applications thereof. Background Art
[0002] The two major habitats of the human body's flora include the oral cavity and the intestine. The oral cavity is a complex microbial environment with about 700 species, which constitute a wide variety of oral flora. There are also a large number of microorganisms in the intestine, about 1000-1500 species, and hundreds of billions or even trillions of bacteria constitute the intestinal flora. Whether it is oral flora or intestinal flora, they have been with the human body since the birth of the baby, forming an indispensable and powerful micro-ecological system for the human body and forming a natural barrier for the human body. The normal balance of flora plays a vital role in the metabolism, immunity, nutrition and other aspects of the human body. However, unhealthy living and eating habits, diseases, intense study and work pressure and other factors may lead to the imbalance of oral and / or intestinal flora in the human body, that is, the number of beneficial bacteria decreases and the number of harmful bacteria or pathogenic bacteria increases, thereby breaking the original balance of flora in the digestive tract and leading to the occurrence and development of related diseases.
[0003] Studies in recent years have found that there are close interactions and influences between oral and intestinal microorganisms. Oral microorganisms can enter the intestine through the digestive tract, affecting the composition and function of intestinal microorganisms. Intestinal microorganisms can also enter the oral cavity through the blood circulation, affecting the composition and function of oral microorganisms. Oral and intestinal microorganisms can change the balance between local and systemic health and disease. Oral microecology and intestinal microecology are closely related to diseases such as obesity, liver fibrosis, inflammatory diseases, sleep disorders, asthma, and pancreatic cancer. Therefore, regulating the balance of oral and intestinal flora is crucial to maintaining human health. Probiotics are a type of active microorganisms that are beneficial to the host by colonizing in the human body and changing the composition of the flora in a certain part of the host. They promote nutrient absorption by regulating the host mucosal and systemic immune function or regulating the balance of intestinal flora, thereby benefiting the host's health.
[0004] Sleep disorders are conditions that prevent people from falling asleep or cause them to wake up too early, and are characterized by functional disorders of sleep quality, sleep quantity and sleep duration. Among sleep disorders, insomnia is particularly well-known, characterized by the inability to fall asleep. Insomnia is associated with poor daytime functioning and is accompanied by symptoms such as tiredness, irritability, learning difficulties, lack of memory consolidation and a significant loss of interest in carrying out daily affairs. Continuous insomnia for more than a few consecutive nights may become a "chronic disease" and lead to insufficient sleep, which is extremely harmful to the health of insomniacs. However, due to a lack of understanding, insomnia is only regarded as a general population with mental imbalance, and people do not pay enough attention to this disease, which is also the reason why most people do not seek treatment. Insomnia increases the risk of cardiovascular disease, as well as a series of diseases such as diabetes, obesity, cancer, stroke, asthma, etc. Insomnia also affects the state of personal work and life, bringing a serious burden to patients and their families.
[0005] As a means of improving sleep quality, the use of sleeping pills as drugs can be considered. Early drug treatment was mainly based on benzodiazepines, but due to the causes of cognitive decline, mental and motor impairment, changes in sleep structure, rebound insomnia, drug dependence, etc., they have gradually been replaced by non-benzodiazepines. Currently, the more commonly used non-benzodiazepines in clinical practice are zopiclone, zolpidem, ezopiclone and zaleplon. Among them, zolpidem is used more. Zolpidem is a short-acting non-benzodiazepine sleeping pill. It is used for insufficient sleep, transient insomnia, and chronic insomnia. Although it has been reported that the approved dose of zolpidem has a certain effect in reducing the sleep latency and increasing the total sleep time of patients with insomnia, it can also effectively improve sleep quality. However, in clinical practice, its effectiveness and safety are still concerned by users.
[0006] Studies have found that probiotics have the functions of regulating the balance of oral and intestinal flora, immune regulation, anti-inflammatory, and antiviral, and can be used to relieve abnormal sleep. However, the effect of using a single probiotic to relieve abnormal sleep is limited. Therefore, how to further improve the effect of probiotics in relieving abnormal sleep is still a technical problem that needs to be solved urgently by those skilled in the art.
[0007] Studies have shown that Lactobacillus acidophilus NCFM from humans TM Helps improve gastrointestinal health, increases the level of natural beneficial bacteria in the body, relieves gastrointestinal discomfort, aids digestion, and maintains a healthy balance of microbiota. TM It also has an immunomodulatory effect and can reduce the symptoms of respiratory infections. Bifidobacterium lactis Bi-07 derived from human body TM It has high tolerance to the gastrointestinal environment and strong adhesion to intestinal cell lines, and can better colonize in the intestines to maintain gastrointestinal health. In particular, clinical studies on Chinese children aged 3-5 years have shown that Lactobacillus acidophilus NCFMTM and Bifidobacterium lactis Bi-07 TM A specific combination of antibiotics can reduce the incidence and duration of fever, runny nose and cough (reducing fever symptoms by 72%, cough by 62% and runny nose by 59%), reduce antibiotic use by 84%, reduce absence from work due to colds by 27% and reduce sick days by 48%.
[0008] Lactobacillus salivarius HA-118, which originates from the human body, contributes to oral health and balances the oral microecology. Lactobacillus salivarius HA-118 can metabolize to produce antibacterial components H 2 O 2 , reducing volatile sulfides in the oral cavity, and has a significant effect on oral odor (bad breath). At the same time, HA-118 has a good inhibitory effect on oral pathogens-Streptococcus mutans. HA-118 has strong oral persistence against periodontal pathogens such as Streptococcus mutans, Streptococcus sanguinis, and Pyrromonas. Lactobacillus helveticus LaftiL10 derived from dairy products can also metabolize to produce antibacterial components H 2 O 2 , significantly reducing volatile sulfides in the oral cavity, and has a significant effect on oral odor (bad breath). Lafti L10 has a good inhibitory effect on Candida albicans and can prevent mucosal infections. Lafti L10 also has the effect of regulating immunity, which can reduce cold symptoms and drug use. Bifidobacterium longum R0175 isolated from the human body can act on the "brain-gut axis" by protecting the intestinal barrier, reducing the production of proinflammatory factors, promoting the synthesis of neurotransmitters, regulating the vagus nerve, etc., and has good anti-depressant and anti-anxiety effects in clinical experiments, thereby having a positive impact on mental health. Lactobacillus rhamnosus R0011 isolated from dairy products has good adhesion in the intestine, can reduce the colonization of Helicobacter pylori and the inflammation caused by it, and can relieve gastric mucosal inflammatory reactions by reducing the colonization of Helicobacter pylori. Combinations of probiotics often have higher clinical efficacy than any single probiotic preparation. The probiotic combination of Lactobacillus salivarius HA-118, Lactobacillus helveticus LaftiL10, Bifidobacterium longum R0175 and Lactobacillus rhamnosus R0011 has also been proven in multiple clinical studies to control the growth of Streptococcus mutans, maintain the pH value of healthy saliva, help reduce or slow the formation of dental plaque, and promote gum health. Compared with widely used mouthwashes containing chlorhexidine or sodium fluoride, this probiotic combination provides similar or better effects. And this specific probiotic combination can regulate the healthy balance of oral microbiota, support the healthy level of Candida in the oral microbiome, and maintain healthy breath.
[0009] Apigenin, chemically named 4,5,7-trihydroxyflavone, is a flavonoid compound. It is widely distributed in nature, mainly in the form of plant yellow pigments in warm and tropical vegetables, fruits, beans, tea, and water hyacinth of the Scrophulariaceae family, Polygonum cuspidatum, Liliaceae hairy-leaved Veratrum, and Pinaceae plants. The highest content is in celery. Apigenin is a natural antioxidant. Modern research has found that apigenin has many pharmacological effects, including anti-tumor, anti-atherosclerosis, anti-thrombosis, anti-virus, antibacterial and anti-inflammatory, diuretic, sedative, tranquilizer, antihypertensive, anti-Parkinson's disease, etc., so it has high medicinal value.
[0010] Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin in improving sleep. Summary of the invention
[0011] The purpose of the present invention is to provide a composition containing probiotics for improving oral and intestinal flora with synergistic effects, so as to provide a new idea for improving sleep safely, effectively, conveniently and economically.
[0012] Specifically, the present invention is realized through the following technical solutions.
[0013] In a first aspect, the present invention provides a composition containing probiotics for improving oral and intestinal flora, the composition comprising Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin.
[0014] In a preferred embodiment of the present invention, the above composition comprises 10-35 parts by weight of Lactobacillus acidophilus NCFM TM 10-35 parts of Bifidobacterium lactis Bi-07 TM , 2.5-15 parts of Lactobacillus salivarius HA-118, 2.5-15 parts of Lactobacillus helveticus Lafti L10, 2.5-10 parts of Bifidobacterium longum R0175, 2.5-10 parts of Lactobacillus rhamnosus R0011 and 15-70 parts of apigenin.
[0015] In a preferred embodiment of the present invention, the above composition comprises 15-30 parts by weight of Lactobacillus acidophilus NCFM TM 15-30 parts of Bifidobacterium lactis Bi-07 TM, 5-10 parts of Lactobacillus salivarius HA-118, 5-10 parts of Lactobacillus helveticus LaftiL10, 5-7.5 parts of Bifidobacterium longum R0175, 5-7.5 parts of Lactobacillus rhamnosus R0011 and 25-55 parts of apigenin.
[0016] In a preferred embodiment of the present invention, in the above composition, the Lactobacillus acidophilus NCFM TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g.
[0017] In a preferred embodiment of the present invention, in the above composition, the Bifidobacterium lactis Bi-07 TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g.
[0018] In a preferred embodiment of the present invention, in the above composition, the viable count of Lactobacillus salivarius HA-118 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0019] In a preferred embodiment of the present invention, in the above composition, the viable count of Lactobacillus helveticus Lafti L10 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0020] In a preferred embodiment of the present invention, in the above composition, the viable count of Bifidobacterium longum R0175 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0021] In a preferred embodiment of the present invention, in the above composition, the viable count of Lactobacillus rhamnosus R0011 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0022] In a preferred embodiment of the present invention, in the above composition, the Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 are freeze-dried bacterial powders.
[0023] In a second aspect, the present invention provides use of the composition described in the first aspect in preparing a product for improving sleep.
[0024] In a preferred embodiment of the present invention, in the above product, the Lactobacillus acidophilus NCFM TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g.
[0025] In a preferred embodiment of the present invention, in the above product, the Bifidobacterium lactis Bi-07 TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g.
[0026] In a preferred embodiment of the present invention, in the above product, the viable count of Lactobacillus salivarius HA-118 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0027] In a preferred embodiment of the present invention, in the above product, the viable count of Lactobacillus helveticus Lafti L10 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0028] In a preferred embodiment of the present invention, in the above product, the viable count of Bifidobacterium longum R0175 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0029] In a preferred embodiment of the present invention, in the above product, the viable count of Lactobacillus rhamnosus R0011 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0030] In a preferred embodiment of the present invention, in the above product, the Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 are freeze-dried bacterial powders.
[0031] In a preferred embodiment of the present invention, the sleep-improving products include medicines, health products and functional foods.
[0032] In a preferred embodiment of the present invention, the sleep improving product may further include a pharmaceutically acceptable carrier or an excipient acceptable to health products or foods, wherein the pharmaceutically acceptable carrier or the excipient acceptable to health products or foods is selected from one or more of a filler, a disintegrant, a lubricant, a binder, a wetting agent, a suspending agent, a surfactant, a flavoring agent, a sweetener, a solvent, an acid source, an alkali source, a pigment, and the like.
[0033] In a preferred embodiment of the present invention, the filler includes but is not limited to corn starch, lactose, pregelatinized starch, microcrystalline cellulose, maltodextrin, etc.; the disintegrant includes but is not limited to starch effervescent mixture, i.e. sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the lubricant includes but is not limited to talc, sodium lauryl sulfate, sodium oleate, stearic acid, poloxamer, magnesium stearate, etc.; the binder includes but is not limited to hydroxypropyl methylcellulose, syrup, starch slurry, sodium carboxymethyl cellulose, etc.; the suspending agent includes but is not limited to polysaccharides such as agar, acacia gum, cellulose ether, alginic acid and carboxymethyl chitosan, etc.; the acid source includes but is not limited to citric acid, tartaric acid, malic acid and citric acid, etc.; the alkali source includes but is not limited to sodium bicarbonate, sodium carbonate, etc.
[0034] In a third aspect, the present invention provides an oral micro-effervescent tablet for improving sleep, wherein the oral micro-effervescent tablet comprises the composition described in the first aspect.
[0035] In a preferred embodiment of the present invention, the above-mentioned oral micro-effervescent tablet further comprises auxiliary materials such as an acid source, an alkali source, a flavoring agent, a sweetener, an essence, and magnesium stearate.
[0036] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the Lactobacillus acidophilus NCFM TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g.
[0037] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the Bifidobacterium lactis Bi-07 TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g.
[0038] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the viable count of Lactobacillus salivarius HA-118 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0039] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the viable count of Lactobacillus helveticus LaftiL10 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0040] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the viable count of Bifidobacterium longum R0175 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0041] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the viable count of Lactobacillus rhamnosus R0011 is 1×10 8 cfu / g-1×10 10 cfu / g.
[0042] In a preferred embodiment of the present invention, in the above-mentioned oral micro-effervescent tablet, the Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 are freeze-dried bacterial powders.
[0043] Microorganism Lactobacillus acidophilus NCFM used in the present invention TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 are all well-known microorganisms to those skilled in the art and can be purchased commercially. The purchased strains only need to meet the requirements of the live bacteria described in the present invention and can be compounded, mixed, and packaged according to known methods. It is also possible to combine the compounded microbial composition with apigenin and acceptable excipients to prepare products of different needs according to known methods for preparing functional foods, medicines, and health products.
[0044] Compared with the prior art, the present invention has the following beneficial effects:
[0045] The present invention creatively develops a composition containing probiotics for improving oral and intestinal flora, by combining a specific dosage ratio of Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TMThe combination of probiotics, Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin can significantly improve the insomnia symptoms of PCPA-induced mice and significantly prolong the duration of sleep. The effect is significantly better than the probiotics, apigenin single use group and the probiotics combined use group. This shows that the combination of Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus LaftiL10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin have a significant synergistic effect on the improvement of sleep, and obtain technical effects that are difficult for technicians in the field to foresee. In addition, the composition of the present invention has no toxic side effects and is easy to use. It can be used to prepare related products for improving sleep and has broad application prospects. DETAILED DESCRIPTION
[0046] The present invention will be further described with reference to specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the scope of the present invention.
[0047] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0048] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.
[0049] Example:
[0050] This example explores the effect of the composition of the present invention containing probiotics for improving oral and intestinal flora on improving sleep in mice:
[0051] 1. Main experimental materials
[0052] Animals: SPF male mice, weighing 16-20 g, were provided by the Animal Experiment Center of Southern Medical University. Before the experiment, the mice were allowed to adapt to the experimental environment and related operations.
[0053] 2. Experimental Methods
[0054] 2.1 After 5 days of adaptation, 90 mice were randomly divided into 9 groups, 10 mice in each group, including blank group, model group, Lactobacillus acidophilus NCFM group, TM Group (NCFM TM Group), Bifidobacterium lactis Bi-07 TM Group (Bi-07 TMgroup), Lactobacillus salivarius HA-118 + Lactobacillus helveticus Lafti L10 group (HA-118 + Lafti L10 group), Bifidobacterium longum R0175 + Lactobacillus rhamnosus R0011 group (R0175 + R0011 group), apigenin group, NCFM TM +Bi-07 TM +HA-118+Lafti L10+R0175+R0011 group, NCFM TM +Bi-07 TM +HA-118+Lafti L10+R0175+R0011+Apigenin group. Each group was gavaged with the corresponding sample for 15 consecutive days. The dosage conversion method for mice was based on the daily consumption of 13 billion cfu of probiotics per person. The average human body weight was 65 kg, and the dosage per kilogram of body weight was 200 million cfu of probiotics. The mouse dosage was 6.5 times that of the human body, that is, 1.3 billion cfu / kg. Each group was given the following dosage:
[0055] (1) Blank group: distilled water
[0056] (2) Model group: distilled water
[0057] (3)NCFM TM Group: 1.3 billion cfu / kg NCFM TM
[0058] (4)Bi-07 TM Group: 1.3 billion cfu / kg Bi-07 TM
[0059] (5) HA-118+Lafti L10 group: 650 million cfu / kg HA-118+650 million cfu / kg Lafti L10
[0060] (6) R0175+R0011 group: 650 million cfu / kg R0175+650 million cfu / kg R0011
[0061] (7) Apigenin group: 90 mg / kg apigenin
[0062] (8)NCFM TM +Bi-07 TM +HA-118+Lafti L10+R0175+R0011 group: 500 million cfu / kg NCFM TM +500 million cfu / kg Bi-07 TM +100 million cfu / kg HA-118+100 million cfu / kg Lafti L10+50 million cfu / kg R0175+50 million cfu / kg R0011
[0063] (9)NCFM TM +Bi-07 TM +HA-118+Lafti L10+R0175+R0011+Apigenin group: 500 million cfu / kg NCFM TM +500 million cfu / kg Bi-07 TM +100 million cfu / kg HA-118+100 million cfu / kg Lafti L10+50 million cfu / kgR0175+500 million cfu / kg R0011+90mg / kg apigenin.
[0064] 2.2 Model Group, NCFM TM Group, Bi-07 TM group, HA-118+Lafti L10 group, R0175+R0011 group, apigenin group, NCFM TM +Bi-07 TM +HA-118+Lafti L10+R0175+R0011 group, NCFM TM +Bi-07 TM The +HA-118+Lafti L10+R0175+R0011+apigenin group was intraperitoneally injected with 500 mg / kg p-chlorophenylalanine (PCPA) suspension for 2 consecutive days, and the blank group was intraperitoneally injected with the same volume of normal saline solution.
[0065] 2.3 20 minutes after the last sample was given, a sodium pentobarbital solution was intraperitoneally injected at a dose of 50 mg / kg. Immediately after the injection, the duration of sleep of the mice was timed, observed and recorded (the time period from the disappearance of the righting reflex to the recovery of the righting reflex). The results are shown in Table 1.
[0066] Table 1: Determination of the improvement effect of the probiotics and their compositions of the present invention on PCPA-induced insomnia in mice
[0067]
[0068]
[0069] 2.4 Experimental results: From Table 1, we can see that compared with the blank group, the sleep duration of mice in the model group was significantly shortened (P<0.01); compared with the model group, NCFM TM +Bi-07 TM +HA-118+Lafti L10+R0175+R0011 group, NCFM TM +Bi-07 TM+HA-118+Lafti L10+R0175+R0011+Apigenin group significantly prolonged the duration of sleep in mice (P<0.01). TM , Bifidobacterium lactis Bi-07 TM When Lactobacillus acidophilus NCFM was used in combination with probiotics, salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin, the combination group could significantly improve the insomnia symptoms of PCPA-induced mice and significantly prolong the duration of sleep, which was significantly better than the probiotics, apigenin single use group and the probiotics combination group. TM , Bifidobacterium lactis Bi-07 TM After the combination of Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin, the improvement of sleep has a significant synergistic effect. Therefore, the composition of the probiotics containing probiotics for improving oral and intestinal flora of the present invention can be used to prepare related products for improving sleep, and has a wide range of application prospects.
[0070] Obviously, the above embodiments are only examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. Those skilled in the art may make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A composition containing probiotics for improving oral and intestinal flora, characterized in that: The composition includes Lactobacillus acidophilus NCFM TM , Bifidobacterium lactis Bi-07 TM , Lactobacillus salivarius HA-118, Lactobacillus helveticus Lafti L10, Bifidobacterium longum R0175, Lactobacillus rhamnosus R0011 and apigenin.
2. The composition according to claim 1, characterized in that By weight, the composition comprises 10-35 parts of Lactobacillus acidophilus NCFM TM 10-35 parts of Bifidobacterium lactis Bi-07 TM , 2.5-15 parts of Lactobacillus salivarius HA-118, 2.5-15 parts of Lactobacillus helveticus Lafti L10, 2.5-10 parts of Bifidobacterium longum R0175, 2.5-10 parts of Lactobacillus rhamnosus R0011 and 15-70 parts of apigenin.
3. The composition according to claim 1, characterized in that By weight, the composition comprises 15-30 parts of Lactobacillus acidophilus NCFM TM 15-30 parts of Bifidobacterium lactis Bi-07 TM , 5-10 parts of Lactobacillus salivarius HA-118, 5-10 parts of Lactobacillus helveticus Lafti L10, 5-7.5 parts of Bifidobacterium longum R0175, 5-7.5 parts of Lactobacillus rhamnosus R0011 and 25-55 parts of apigenin.
4. The composition according to claim 1, characterized in that The Lactobacillus acidophilus NCFM TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g; the Bifidobacterium lactis Bi-07 TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus salivarius HA-118 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus helveticus Lafti L10 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Bifidobacterium longum R0175 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus rhamnosus R0011 is 1×10 8 cfu / g-1×10 10 cfu / g.
5. Use of the composition according to any one of claims 1 to 4 in the preparation of a product for improving sleep.
6. The use according to claim 5, characterized in that: The sleep-improving products include medicines, health products and functional foods.
7. The use according to claim 5 or 6, characterized in that: In the product, Lactobacillus acidophilus NCFM TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g; Bifidobacterium lactis Bi-07 TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus salivarius HA-118 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus helveticus Lafti L10 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Bifidobacterium longum R0175 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus rhamnosus R0011 was 1×10 8 cfu / g-1×10 10 cfu / g.
8. An oral micro-effervescent tablet for improving sleep, characterized in that: The oral micro-effervescent tablet comprises the composition according to any one of claims 1 to 4.
9. The oral micro-effervescent tablet according to claim 8, characterized in that: In the oral micro-effervescent tablet, Lactobacillus acidophilus NCFM TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g; Bifidobacterium lactis Bi-07 TM The number of viable bacteria is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus salivarius HA-118 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus helveticus Lafti L10 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Bifidobacterium longum R0175 is 1×10 8 cfu / g-1×10 10 cfu / g; the viable count of Lactobacillus rhamnosus R0011 was 1×10 8 cfu / g-1×10 10 cfu / g.
